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Statins help to maintain the cholesterol level and 
decrease cardiovascular complications.1 They are 
therefore a widely prescribed therapeutic class. 
However, several studies indicate that approximately 
50% of patients discontinue statin therapy within the 
first year of prescription.2,3 There are many reasons for 
poor adherence to treatment, but the over-occurrence 
of muscular effects is an important cause. Thus, 
myalgia on statins is a veritable clinical challenge. In 
this article, we propose to analyze the different forms 
of muscle complications under statins, their frequency, 
the difficulty of their diagnosis, the factors favoring 
their occurrence, the influence of the dose and the 
molecule prescribed, the mechanisms involved in 
statin muscle toxicity, and their management, in 
clinical practice. Myopathy is used broadly to describe 
any  statin-related  muscle  side  effect. Myalgia 
describes any muscle pain, without creatine  
phosphokinase  (CPK)  elevation.  
 
The term “Myositis" is  used  for  muscle  
manifestations  with increased CPK. Rhabdomyolysis 
defines a serious complication including muscle pain, 
significant elevation of CPK (>10 times the upper limit 
of normal), increased creatinine, and usually dark 
urine with myoglobinuria.  Besides the classic form of  
statin-induced rhabdomyolysis,  a  very  rare  form  of  
statin-induced  autoimmune rhabdomyolysis  has  
been  described.4  This rare form, characterized by the 




treatment with glucocorticoids, immunosuppressants, 
and immunoglobulins.4 The muscle effects of  statins 
represent  a  continuum  from normal   CPK   muscle   
soreness   to   rare   cases   of rhabdomyolysis.  They 
usually appear a few weeks after initiation of therapy, 
but can  sometimes  be  seen  several years after 
initiation of statin therapy. 
 
The frequency of muscle complications on statins is 
difficult to define precisely. In controlled clinical 
studies, the frequency of muscle side effects is 
estimated to be between 1.5% and 5.0%.5 Often, the 
frequency of muscular side effects does not appear 
significantly higher in patients on statins than in those 
on placebo. The rather low frequency of muscle side 
effects in "controlled" intervention studies may be 
explained by several reasons: the non-inclusion of mild 
to moderate muscle pain in the studies, the exclusion 
of any subject with a history of myopathy on statins or 
who had muscle pain during the run-in phase, and the 
biased psychological profile of patients agreeing to 
participate in clinical studies.6 Thus, observational 
studies and daily clinical data show a higher frequency 
of muscle side effects on statins. In 4% of the patients 
in the study, there was disabling pain for daily physical 
activity, and in 0.4%, severe pain requiring cessation of 
any activity including professional.7 The US 
Understanding Statin Use in America and Gaps in 
Education study found a 25% prevalence of muscle side 
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the link between reported muscle pain and statin 
liability is not always clear. Many environmental or 
cultural factors could also be involved in patients' 
blaming statin therapy for the occurrence of muscle 
disorders. For example, in an international survey, the 
occurrence of unbearable muscle pain on statins was 
reported in an average of 6% of patients, with 
significant differences between countries, ranging 
from 2% for Italy, Spain, Japan and Sweden, to a rate 
between 10% and 12% for Canada, the UK and the 
USA.9 It is highly likely that the frequency of muscle 
effects of statins is overestimated by patients.10 These 
data confirm that not all muscle pain experienced by 
patients is necessarily related to statins. Thus, while 
the prevalence of muscle effects on statins is likely to 
be underestimated by interventional studies, it is 
clearly overestimated in observational studies and 
routine clinical practice where any muscle 
symptomatology presented is not necessarily 
secondary to statin treatment. However, evidence for a 
direct effect of statins is provided by a double-blind 
controlled study objectifying a largely reversible 
mitochondrial myopathy in patients with normal CPK 
myalgias on statin.11 
 
Diagnosis of statin liability in the face of muscle 
symptomatology is not obvious, particularly in the 
absence of CPK elevation. Risk factors for the 
occurrence of muscle complications on statins include 
advancing age, female gender, low body mass index, 
genetic makeup, intense physical activity, kidney or 
liver failure, hypothyroidism, inherited or metabolic 
myopathies and excessive alcohol. A few drugs namely 
fibrates, nicotinic acid, ciclosporin, digoxin, 
antifungals, macrolides, erythromycin, clarithromycin, 
protease inhibitors, verapamil, diltiazem and 
amiodarone are also known risk factors to the 
occurrence of muscle complications. A genetic 
polymorphism affecting the OATBP1 transporter, 
responsible for the uptake of statins by the liver, has 
been authenticated as a factor increasing the risk of 
statin myopathy.12  
 
Several data strongly suggest that the occurrence of 
muscle effects is influenced by statin dose. Muscle 
biopsies from patients with muscle effects secondary 
to statin use have shown muscle cell necrosis with 
mitochondrial functional abnormalities.13 The 
pathophysiological mechanisms responsible for the 
muscular effects of statins are not fully elucidated, but 
several hypotheses have been put forward: Depletion 
of ubiquinone is a suggested one. The latter is involved 
in the transport of electrons in the mitochondria and 
its reduction is likely to impair mitochondrial function. 
The exact role of ubiquinone, or coenzyme Q10, 
depletion in the occurrence of statin muscle effects is 
still debated. Indeed, a study performed after 6 months 
of treatment with simvastatin 20 mg/d did not 
demonstrate a decrease in ubiquinone concentration 
at the muscle level.14 Another randomized study 
objectified an efficacy of coenzyme Q10 
supplementation in reducing muscle pain on statins.15 
Depletion of isoprenoids is other popular mechanism. 
It has also been suggested that the reduction of 
cholesterol content within myocyte membranes may 
modify the fluidity of the cell membrane, and thus the 
proper function of ion transporters. This dysfunction 
of the myocyte membrane could cause cramping and 
myalgia. This hypothesis remains to be confirmed. 
Modification of the calcium balance in the muscle cell 
is another proposed mechanism. Statins inhibit 
mitochondrial respiratory chain complex with 
consequent depolarization of the inner membrane 
promoting calcium efflux from the mitochondria to the 
cytoplasm.16  
 
Excess cytoplasmic calcium is recaptured by the 
sarcoplasmic reticulum. However, excess calcium 
within the sarcoplasmic reticulum is released into the 
cytoplasm via the ryanodine receptor. It has been 
suggested that statins may also directly activate the 
ryanodine receptor thereby enhancing excess calcium 
in the cytoplasm.16 Calcium overload in the cytoplasm 
promotes cramping, myalgia and muscle cell 
apoptosis. Management of myalgia due statins starts 
with assessment of the intensity and tolerance of the 
pain, and its nature, whether permanent or transient, 
as well as possible triggering circumstances, such as 
unusual physical activity or sports. Concomitant 
medications that add as a risk factor to myalgia should 
be considered. If the CPK exceeds 10 times the upper 
limit of normal, it is imperative to stop the statin and 
perform urgently a plasma creatinine assay and a 
myoglobinuria search. Close clinical and biological 
monitoring should be implemented. In case of frank 
rhabdomyolysis, vascular filling should be started, 
without delay. If the CPK level is normal or increased, 
but less than 10 times the upper limit of normal, the 
dose of statins should be reduced, or treatment should 
be withheld altogether. If CPK values exceed 5 times 
the upper limit of normal or significant muscle pain, 
transient discontinuation of treatment is strongly 
advised. If CPK levels are increased, CPK checks should 
be performed every 1-2 weeks. If muscle pain persists 
after stopping statin therapy, it is necessary to look for 
another cause of muscle damage and to perform an 
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electromyogram. Alternatively, alternating treatments 
may be suggested like long half-life statins. Before 
declaring a patient completely statin intolerant, it 
seems important to try several alternatives with statins 
and not to abandon statin therapy too quickly. In case 
of frank intolerance to statins after several attempts, 
another treatment strategies should be tried.  
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